A new analysis from the Tufts Center for the Study of Drug Development (CSDD) found that an AI clinical monitoring agent can deliver an estimated 82-fold return on investment in phase 3 oncology trials.
AI clinical monitoring agent can deliver up to 82 times the ROI in oncology: report
Post navigation
Previous Post
Spain Clarifies Neonatology’s Legal and Training StatusNext Post
Next 10 U.S. Biopharma Clusters 